Neogen Corporation Business Acquisition, Pro Forma Net Income (Loss)
Neogen Corporation (NEOG) reported Business Acquisition, Pro Forma Net Income (Loss) of $5.40 million for the 12-month period ending 2022-05-31, per its 10-K filed 2022-07-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2022-07-27
- Neogen Corporation business acquisition, pro forma net income (loss) for fiscal 2022 was $5.40M, a 28.57% increase from fiscal 2021.
- Neogen Corporation business acquisition, pro forma net income (loss) for fiscal 2021 was $4.20M, a 707.69% increase from fiscal 2020.
- Neogen Corporation business acquisition, pro forma net income (loss) for fiscal 2020 was $520.00K.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2022-05-31 | $5.40M 10-K · filed 2022-07-27 |
| 2021-05-31 | $4.20M 10-K · filed 2022-07-27 |
| 2020-05-31 | $520.00K 10-K · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |